Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) was up 4.9% on Friday . The stock traded as high as $5.77 and last traded at $5.70. Approximately 922,095 shares changed hands during trading, a decline of 44% from the average daily volume of 1,640,261 shares. The stock had previously closed at $5.43.
Analyst Upgrades and Downgrades
Several research firms have commented on XERS. Jefferies Financial Group restated a "buy" rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Leerink Partners boosted their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. Craig Hallum upped their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Piper Sandler restated a "neutral" rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $5.92.
View Our Latest Stock Report on Xeris Biopharma
Xeris Biopharma Price Performance
The firm's 50 day simple moving average is $3.99 and its 200-day simple moving average is $3.46. The company has a market capitalization of $903.63 million, a PE ratio of -13.04 and a beta of 2.32.
Insider Activity at Xeris Biopharma
In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.56% of the company's stock.
Institutional Investors Weigh In On Xeris Biopharma
Several institutional investors and hedge funds have recently modified their holdings of the stock. Walleye Capital LLC acquired a new position in Xeris Biopharma during the 3rd quarter worth approximately $3,197,000. JPMorgan Chase & Co. raised its stake in shares of Xeris Biopharma by 166.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock valued at $3,537,000 after purchasing an additional 651,481 shares during the period. Driehaus Capital Management LLC acquired a new position in shares of Xeris Biopharma during the fourth quarter worth $2,014,000. Millennium Management LLC boosted its stake in shares of Xeris Biopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after purchasing an additional 502,853 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Xeris Biopharma by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock valued at $7,115,000 after purchasing an additional 500,120 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Further Reading
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
